Failure of papaverine to alter L-dopa-influenced GH and PRL secretion.
Papaverine, 150 mg BID for 2 weeks, a dose which produced marked clinical impairment in Parkinsonian patients taking L-Dopa, failed to alter L-Dopa-stimulated GH secretion or L-Dopa inhibited PRL secretion in 6 normal volunteers. Failure to demonstrate an inhibitory effect of papaverine on dopaminergic hypothalamic-pituitary systems, despite its inhibition of striatal dopaminergic pathways, may imply qualitative or quantitative functional differences between hypothalamic and striatal dopaminergic systems.
D000328:Adult; D005260:Female; D013006:Growth Hormone / Q000378:metabolism*; D006801:Humans; D007980:Levodopa / Q000494:pharmacology*; D008297:Male; D010208:Papaverine / Q000494:pharmacology*; D011388:Prolactin / Q000378:metabolism*
D007980:Levodopa; D011388:Prolactin; D013006:Growth Hormone; D010208:Papaverine